$HIMS: Can the 2030 Target Survive a 2029 White House?

Peptides Add $0 $HIMS’s Q3

$HIMS Up 5% on Peptides. Now Watch This $22B Number

$HIMS: 3 Signs in 50 Days Point to a Global Rollout

$HIMS Launched A Testosterone Pill

How $HIMS Could Earn a Netflix-Style Margin

Is $HIMS Germany a Real Thesis or Just a Viral Rumor?

$HIMS Up 10% - Here’s the End Of Year Setup

4 Signals the $HIMS Peptide Thesis Is Closer Than We Thought

The $HIMS FTC Lawsuit, Explained Simply

$HIMS Earnings Setup: The Number That Would Change My Mind

The $HIMS $500 Thesis, Explained With Simple Math

HIMS Still A Buy After Canada’s Generic Ozempic

$HIMS Signal: Teladoc's Cash-Pay Arm Fell 20%.

$HIMS Faces 50% Cheaper GLP-1s

How $HIMS Got Into Australia - And Why It's Fragile

Inflation is back. Is $HIMS built for it?

$HIMS CEO Just Predicted His Own Price War

How the $HIMS FTC Case Could End: Settlement Path Explained

Could GLP-1 Churn Hit 65%?

Samsung Just Paid 1.8 Billion For a Peptide Factory

Is HIMS Still A Buy After Lilly's Move?

$HIMS Grew 38%. Almost None Of It Was Built.

How $HIMS Got To $92 A Month Per Subscriber — And Why It's Fragile

Is $HIMS Still a Buy After the FTC and Visa Hits?

3 Numbers That Decide If $HIMS Reaches $80

Is $HIMS's earnings beat actually good news?

Watch This Before $HIMS Reports Monday

Is $HIMS Still A $35 Stock After The FTC Lawsuit?

This Matters More Than You Think For HIMS

The FTC Just Escalated on $HIMS - For Real This Time

$HIMS Just Passed the FDA Vote - And Got Sold Anyway

Watch This Before the July 23 FDA Peptide Vote

$HIMS's CAO Exit Timeline Doesn't Match the Panic

Is $HIMS Still a Buy After Its GLP-1 Strategy Shift?

$HIMS Isn't Selling Medicine - The Emotional Moat

The GLP-1 Economy, Explained for Retail Investors

He Owns 224,000 HIMS Shares. Here's His Real Take

$HIMS Built the Infrastructure for a New GLP-1 2.0 Run

$Hims Doesn't Care If You Lose Weight

The GLP-1 Price Crash Isn't a Threat to HIMS. It's the Thesis.

FDA Just Sent Two Opposite Signals For Peptides This Will Effect $HIMS

A Third of the Float Is Short — And the Stock Just Popped 41%

$HIMS Went Up 48%. Here's How Much of That Was Real.

From $13 To $35: The Comeback Has Started

Big Pharma Built for 2005. $HIMS Built for Now.

Before You Buy HIMS, Watch This

Netflix Beat Blockbuster. Uber Beat Taxis. Who Beats CVS?

2.6 Million Americans Just Handed $HIMS Their Secrets

The Data That Predicted HIMS Earnings Twice Just Flashed a New Signal

Every Generation Has Its Stock. Here's Why Gen Z's Might Be HIMS.

$1.15 Billion. For a Money-Losing Company. Why Hims Just Made a Global Land Grab.

Hims Crashed. Then The CEO And The Board Did Something Unusual.

Netflix's Former CFO Just Bought $1.17M Of $HIMS

$HIMS: -37% Downside. +152% Upside. Here's The Math.

Here's the most underestimated catalyst in the entire $HIMS short squeeze thesis

The Investor Who Called Palantir, AMD, and Robinhood Just Said This About $HIMS

This one event could completely reprice $HIMS - and it's happening in 2026.

Here are 3 signs the worst is over for $HIMS

$HIMS raised $350 million at 0%. The stock dropped. Here's what actually happened.